Loading...
Loading...
Browse all stories on DeepNewz
VisitCEO Pascal Soriot's status with AstraZeneca by 2025
Remains as CEO • 33%
Steps down • 33%
Extended or new contract • 34%
AstraZeneca press releases and major news outlets
AstraZeneca Targets $80 Billion Revenue by 2030 with 75% Growth and 20 New Medicines
May 21, 2024, 10:22 AM
AstraZeneca has set an ambitious target to achieve $80 billion in total revenue by 2030, nearly doubling its revenue from the previous year’s $45.81 billion. The British drugmaker plans to launch 20 new medicines by 2030, which are expected to significantly contribute to this growth. CEO Pascal Soriot aims to solidify his legacy through this expansion, which will also be driven by growth in the company's existing oncology, biopharmaceuticals, and rare disease portfolios. This new revenue goal surpasses analyst forecasts and highlights AstraZeneca's confidence in its pipeline, which features several potential $5 billion-plus candidates.
View original story
$50 Billion • 25%
$60 Billion • 25%
$70 Billion • 25%
$80 Billion • 25%
Stock price increases • 33%
Stock price decreases • 33%
Stock price remains stable • 34%
Less than 5 • 25%
5 to 9 • 25%
10 to 14 • 25%
15 or more • 25%
Oncology • 33%
Biopharmaceuticals • 33%
Rare Diseases • 33%
More lawsuits filed • 33%
No additional lawsuits • 33%
Class action lawsuit initiated • 34%
Other • 25%
Oncology • 25%
Biopharmaceuticals • 25%
Rare diseases • 25%